HØRSHOLM, DK / ACCESS Newswire / June 30, 2025 / Gubra (CPH:GUBRA) Today, 30 June 2025, Gubra shares are traded ex-dividend of DKK 61.20. Contacts at Gubra Media: Sofia Pitt Boserup, [email protected] ...

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.

HØRSHOLM, DK / ACCESS Newswire / June 30, 2025 / Gubra (CPH:GUBRA) Today, 30 June 2025, Gubra shares are traded ex-dividend of DKK 61.20. Contacts at Gubra Media: Sofia Pitt Boserup, [email protected] , ...

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.

Contacts at Gubra Media: Sofia Pitt Boserup, [email protected], +45 4188 9586 Investors: Kristian Borbos, [email protected], +45 3080 8035 About Gubra Gubra, founded in 2008 in Denmark, listed on Nasdaq ...

Contacts at Gubra Media: Sofia Pitt Boserup, [email protected], +45 4188 9586 Investors: Kristian Borbos, [email protected], +45 3080 8035 About Gubra ...

Gubra Announces Positive GUBamy Phase 1 Interim MAD Results HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA) GUBamy was well tolerated with adverse events being predominantly GI ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits ...

Imagine a world without disease. Sounds utopian? AI just made it a multibillion-dollar bet to discover drugs – and forget Big ...

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion. The ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...